Cellerix Report issue

For profit Phase 2 Phase 3
Founded: Madrid Spain (2004)
Status: Acquired by TiGenix (2011) → now Takeda (2018)

Organization Overview

First Clinical Trial
2006
NCT00987142
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

allogeneic adipose derived mesenchymal stem cell (3 trials)

human fibrin (Tisseel) (1 trial)

Drugs in Phase 2 Trials (1)

cx501 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Crohn Disease (Phase 3)

Epidermolysis Bullosa (Phase 2)

Fistula (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Rectal Fistula (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3